About Us

Internationally renowned Professors David Kerr and Nick La Thangue started OCB from the laboratories of the University of Oxford in 2012. Their aim was to discover and develop biomarkers using screening platforms to advance personalised medicine within oncology, specifically colorectal cancer and its treatments.

Since then, we have built a world class development team consisting of industry professionals, leading scientists and oncologists, retaining strong links to Oxford University. Together we have developed pioneering biomarker technology products that put each individual patient at the centre of cancer treatment.

Management team

  • Dr Guy Mozolowski PhD ARCS FIBMS Chief Operating Officer

    Guy has 15 years’ experience designing, developing and launching a range of high throughput assay platforms and in vitro diagnostic systems across the pharmaceutical, clinical, food, dairy and brewing industries. He has collaborated on both commercial governmental and academic projects with institutions such as the Max Plank Institute, the Sanger Centre, the Fraunhofer Institute, Danone, Diageo, Abbott Diagnostics, Pfizer, Novartis, Lilly and MSD. In the course of his career he has lead projects across the US, Europe, the Middle East and Africa.

  • David Kerr CBE MD DSc FRCP (Glas, Lon, Edin) FRCGP FMedSci Founder

    David is a founder of OCB and Professor of Cancer Medicine at the University of Oxford, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. David has an international reputation for the treatment of, and research into, colorectal cancer and the quality of his work has been recognised by the award of several international prizes and the first NHS Nye-Bevan award for innovation.

    David has made a significant contribution to reforming the NHS as a Founding Commissioner for Health Improvement, Chair of the National Cancer Services Collaborative, instigator of the Department of Health’s networked approach to clinical cancer research and he developed a 20 year plan for the future of the NHS in Scotland, the “Kerr Report”. David was elected Fellow of the Academy of Medical Sciences in 2000, Honorary Fellow of Royal College of General Practitioners in 2007, appointed Commander of the British Empire in 2002 and was elected President of the European Society of Medical Oncology in 2010.

  • Dr Susan Fotheringham MSc PhD Scientific and Technical Director

    Susan is a senior scientist with expertise in developing new and improved therapies in cancer with a focus on stratification of patients and personalised medicine. Before joining OCB, she developed a model system studying the role of the fallopian tube as a site-of-origin for serous ovarian cancer in her post-doctor research in Dana-Farber Cancer Institute/Harvard Medical School and studied clinical relevance of the biomarker HR23B in patient stratification for HDAC inhibitor cancer drugs in Oxford University.


  • Dr Kevin Xu BSc PhD Director of Computational Pathology

    Kevin is a senior biomedical data scientist/engineer and highly experienced medical device software product development manager with a focus in digital pathology. Before joining OCB, he was a Lead Software Engineer in Tactiq Limited (originated from GE Healthcare), led the software development and managed the CE-marking process of a number biomedical products including the world-fast PCR thermal cycler. Prior to that, he had been a research fellow in the Applied Optics Group in Nottingham University and a Senior Technical Consultant for commercial software development in Hewlett-Packard UK.


  • Mohammed Jamal Director

    Mr Jamal has over 18 years of experience in structuring, placement, trading, private equity and liquid Investing. Mr Jamal started his career at Morgan Stanley in the structured credit team in 2003. In 2009 Mr Jamal moved to Resource America a $15Bn credit fund to lead their business in Europe.In 2012 Mr Jamal founded Molton Street Capital a London based CLO, CDO and ABS trading company that traded over $3Bn.In 2016 Mr Jamal co-founded Forepont Capital Group, a leading life science Venture Capital fund with office in London, New York and ParisMr Jamal invested in more than 20 companies since 2012 and made multiple successful exits.Mr Jamal holds a Masters degree in Applied Mathematics and Computer Sciences from Ecole Centrale Paris (top French “ Grande Ecole” ) and an advanced degree (DEA) in Finance and Economics from La Sorbonne University in Paris.

  • Nick LaThangue BSc MSc PhD MA Director and Founder

    Nick is a founder of OCB and Professor of Cancer Biology at the University of Oxford. He is a Fellow of the Royal Society of Edinburgh, a Member of the European Molecular Biology Organisation (EMBO), a Fellow of the Academy of Medical Sciences, a Fellow of the Lister Institute and Professorial Fellow at Linacre College Oxford. Nick has founded several companies, including Prolifix and Celleron Therapeutics, and more recently Oxford Cancer Biomarkers, and has considerable experience derived from the biotechnology and pharmaceutical sectors. He served as Chief Business Development Officer and Chief Scientific Officer of TopoTarget, and engineered the IPO on the Scandinavian Stock Exchange.

  • BK Lee Non-Executive Director

    Mr. Lee is a professional investor with extensive experience in investing in biotech and technology. He was previously involved in foreign currency trading at the Bank of New York based in Seoul. He also served as President of Sudokwon Environment Co. Currently Mr. Lee is CEO of Muhan Corporation, a Seoul-based environmental company, and CEO of 29 Investment Corporation, an investment company in Vietnam.

  • Kyoung Mee Lee PhD Non-Executive Director

    Kyoung Mee Lee holds a doctorate in Immuno-Pathology and has worked for 20 years in the biotech/pharmaceutical area.  Before joining Kwangdong Pharma (KDP) in 2006, she worked in the monoclonal antibody therapeutics field. Whilst at KDP she has worked in New Drug Development and external R&D.  Currently she is the Leader of the New Business Team focussing on open innovation to expand business opportunities.  Previously she led the development of an anti-obesity drug candidate. Her Ph.D. was obtained at Chung-Buk National University in Korea where she studied microbiology and immuno-pathology.